Pramlintide
FDA ApprovedAlso known as: Symlin, Amylin Analog
MetabolicLast reviewed: April 28, 2026
A synthetic analog of amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. Represents the amylin pathway that cagrilintide (investigational) also targets.
Mechanism of Action
Mimics the effects of amylin: slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety. These effects complement insulin therapy by reducing postprandial glucose spikes and caloric intake.
Common Uses
- Type 1 diabetes (adjunct to insulin)
- Type 2 diabetes (adjunct to insulin)
- Postprandial glucose control
- Modest weight loss
Known Risks
- Severe hypoglycemia (especially in type 1 diabetes — boxed warning)
- Nausea (common, usually transient)
- Headache
- Anorexia
- Requires careful insulin dose adjustment
Regulatory Status
FDA-approved as Symlin (2005) for type 1 and type 2 diabetes as an adjunct to mealtime insulin. Requires insulin dose reduction to prevent hypoglycemia. Pen injector for self-administration.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
15–120 mcg (titrated by diabetes type)
Frequency
Before major meals
Cycle Length
Ongoing
Type 1: start 15 mcg, titrate to 30-60 mcg. Type 2: start 60 mcg, titrate to 120 mcg. MUST reduce mealtime insulin by 50% when starting. Inject in abdomen or thigh, separate from insulin injection site.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.